Harel Dahari, PhD


Assistant Professor

Languages Spoken



  • Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections Gutfraind, A.; Boodram, B.; Prachand, N.; Hailegiorgis, A.; Dahari, H.; Major, M. E., PLoS ONE
  • Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago Echevarria, D.; Gutfraind, A.; Boodram, B.; Major, M.; Del Valle, S.; Cotler, S. J.; Dahari, H., PLoS ONE
  • Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised double-blind, placebo-controlled phase 2A trial, Koh, C.; Canini, L.; Dahari, H.; Zhao, X.; Uprichard, S. L.; Haynes-Williams, V.; Winters, M. A.; Subramanya, G.; Cooper, S. L.; Pinto, P.; Wolff, E. F.; Bishop, R.; Ai Thanda Han, M.; Cotler, S. J.; Kleiner, D. E.; Keskin, O.; Idilman, R.; Yurdaydin, C.; Glenn, J. S.; Heller, T., The Lancet.Infectious diseases
View All ResearchShow Less
  • Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach Graw, F.; Martin, D. N.; Perelson, A. S.; Uprichard, S. L.; Dahari, H., Journal of virology
  • Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics Dahari, H.; Shteingart, S.; Gafanovich, I.; Cotler, S. J.; D'Amato, M.; Pohl, R. T.; Weiss, G.; Ashkenazi, Y. J.; Tichler, T.; Goldin, E.; Lurie, Y., Liver international : official journal of the International Association for the Study of the Liver
  • Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C Rotman, Y.; Noureddin, M.; Feld, J. J.; Guedj, J.; Witthaus, M.; Han, H.; Park, Y. J.; Park, S. H.; Heller, T.; Ghany, M. G.; Doo, E.; Koh, C.; Abdalla, A.; Gara, N.; Sarkar, S.; Thomas, E.; Ahlenstiel, G.; Edlich, B.; Titerence, R.; Hogdal, L.; Rehermann, B.; Dahari, H.; Perelson, A. S.; Hoofnagle, J. H.; Liang, T. J., Gut
  • Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach Dahari, H.; Cotler, S. J., Hepatology (Baltimore, Md.)
  • Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling Guedj, J.; Rotman, Y.; Cotler, S. J.; Koh, C.; Schmid, P.; Albrecht, J.; Haynes-Williams, V.; Liang, T. J.; Hoofnagle, J. H.; Heller, T.; Dahari, H., Hepatology (Baltimore, Md.)
  • Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model Rong, L.; Guedj, J.; Dahari, H.; Coffield, D. J., Jr; Levi, M.; Smith, P.; Perelson, A. S., PLoS computational biology
  • Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Guedj, J.; Dahari, H.; Rong, L.; Sansone, N. D.; Nettles, R. E.; Cotler, S. J.; Layden, T. J.; Uprichard, S. L.; Perelson, A. S., Proceedings of the National Academy of Sciences of the United States of America
  • Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection Zhang, J.; Lipton, H. L.; Perelson, A. S.; Dahari, H., Journal of virology
  • Silymarin for HCV infection Polyak, S. J.; Oberlies, N. H.; Pecheur, E. I.; Dahari, H.; Ferenci, P.; Pawlotsky, J. M., ANTIVIRAL THERAPY
  • The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate Guedj, J.; Dahari, H.; Uprichard, S. L.; Perelson, A. S., Expert review of gastroenterology & hepatology
  • Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling Dahari, H.; Cotler, S. J.; Layden, T. J.; Perelson, A. S., Journal of Hepatology
  • The rate of hepatitis C virus infection initiation in vitro is directly related to particle density Sabahi, A.; Marsh, K. A.; Dahari, H.; Corcoran, P.; Lamora, J. M.; Yu, X.; Garry, R. F.; Uprichard, S. L., Virology
  • Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon Dahari, H.; Sainz, B., Jr; Perelson, A. S.; Uprichard, S. L., Journal of virology